Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
205.22
+7.09 (3.58%)
At close: Mar 9, 2026, 4:00 PM EDT
206.00
+0.78 (0.38%)
After-hours: Mar 9, 2026, 6:12 PM EDT
Natera Revenue
In the year 2025, Natera had annual revenue of $2.31B with 35.90% growth. Natera had revenue of $665.50M in the quarter ending December 31, 2025, with 39.79% growth.
Revenue (ttm)
$2.31B
Revenue Growth
+35.90%
P/S Ratio
12.40
Revenue / Employee
$375,588
Employees
6,140
Market Cap
29.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.31B | 609.20M | 35.90% |
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IQVIA Holdings | 16.31B |
| Labcorp Holdings | 13.95B |
| Quest Diagnostics | 11.04B |
| Agilent Technologies | 7.07B |
| Illumina | 4.34B |
| IDEXX Laboratories | 4.30B |
| Mettler-Toledo International | 4.03B |
| Exact Sciences | 3.25B |
NTRA News
- 4 days ago - Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript - Seeking Alpha
- 5 days ago - Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 10 days ago - Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation - Business Wire
- 10 days ago - Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors - Seeking Alpha
- 11 days ago - Natera Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 13 days ago - Alger SICAV - Alger Dynamic Opportunities Fund Q4 2025 Portfolio Update - Seeking Alpha
- 13 days ago - Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer - Business Wire